Get the Stockscreener App
269.11
0.72%
-1.9143
Alnylam Pharmaceuticals Inc stock is traded at $269.11, with a volume of 101.36K.
It is down -0.72% in the last 24 hours and up +9.04% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$271.02
Open:
$270.51
24h Volume:
101.36K
Relative Volume:
0.14
Market Cap:
$35.08B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-124.01
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
-5.04%
1M Performance:
+9.04%
6M Performance:
-2.13%
1Y Performance:
+80.03%
1-Day Range:
$264.88
$270.51
1-Week Range:
$264.13
$300.90
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
269.13 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.01 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.56 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.88 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
273.83 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam and Tekmira Restructure Relationship and Settle All Litigation - AOL
Alnylam CEO's compensation package continues to grow - NBC Boston
Alnylam CEO’s compensation package continues to grow - The Business Journals
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Yahoo Finance
Transthyretin Amyloidosis Treatment Market Detailed In New - openPR
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock By Investing.com - Investing.com Australia
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - MSN
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com India
FDA approves new drug to treat protein buildup in the heart - UPI News
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga
FDA OKs Amvuttra To Treat Heart Conditions - The Daily Courier
RBC Capital holds $330 target on Alnylam stock post-Amvuttra approval - Investing.com
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis - Value the Markets
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280 - Marketscreener.com
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
JPMorgan raises Alnylam stock rating, lifts target to $328 - Investing.com
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision - Simply Wall St
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? - Benzinga
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer - MSN
Alnylam price target raised to $338 from $300 at Scotiabank - Yahoo Finance
Alnylam Pharmaceuticals’ SWOT analysis: RNAi leader’s stock poised for growth in ATTR-CM market - Investing.com
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Alnylam Stock Jumps After the FDA Approves Its Heart Drug - The Wall Street Journal
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (NASDAQ:ALNY) - Seeking Alpha
U.S. Markets Moved Upward Friday; Alnylam Pharmaceuticals Climbed Highest - Barron's
Alnylam: US Approval of Amvuttra in ATTR-CM Significantly Expands Addressable Patient Population - Morningstar
Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease - Endpoints News
Buy, Sell, Or Hold Alnylam Stock At $280? - Forbes
Check Out What Whales Are Doing With ALNY - Benzinga
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval - TipRanks
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - TradingView
Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects - MSN
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Expanded Heart Drug Approval Sets Up Pfizer Challenge - MSN
Alnylam's Amvuttra Gains Expanded US Approval for Heart ConditionNews and Statistics - IndexBox, Inc.
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating - Marketscreener.com
Alnylam Pharmaceuticals Shares Rise After Receipt of US FDA Approval for ATTR-CM Drug - Marketscreener.com
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga
Sector Update: Health Care -March 21, 2025 at 09:20 am EDT - Marketscreener.com
Sector Update: Health Care - TradingView
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating - Marketscreener.com
Alnylam scores a first with FDA nod for Amvuttra in ATTR-CM - The Pharma Letter
Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com
Alnylam stock rises after FDA nod for AMVUTTRA By Investing.com - Investing.com Canada
Alnylam joins three-way contest in ATTR cardiomyopathy - pharmaphorum
Alnylam’s SWOT analysis: biotechnology stock poised for growth amid ATTR-CM market expansion - Investing.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 24 '25 |
Sale |
300.00 |
5,445 |
1,633,500 |
20,221 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 21 '25 |
Sale |
285.00 |
4,321 |
1,231,485 |
20,221 |
| PYOTT DAVID E I | Director |
Mar 24 '25 |
Option Exercise |
88.95 |
7,440 |
661,788 |
7,576 |
| PYOTT DAVID E I | Director |
Mar 24 '25 |
Sale |
299.00 |
7,440 |
2,224,560 |
136 |
0.21%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):